AuranofinCAS: 34031-32-8
MF: C20H34AuO9PS
MW: 678.48
An inhibitor of 5-LO (5-lipoxygenase)/LTA synthase and IKK.

Auranofin (CAS 34031-32-8)

Auranofin | CAS 34031-32-8 is rated 5.0 out of 5 by 1.
  • y_2020, m_1, d_24, h_12
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.4
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202476, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 205ms
Synonym: SKF 39162; 1-Thio-β-D-glucopyranosatotriethyl phosphine gold-2,3,4,6-tetraacetate; NSC 321521
Application: An inhibitor of 5-LO (5-lipoxygenase)/LTA synthase and IKK
CAS Number: 34031-32-8
Purity: ≥95%
Molecular Weight: 678.48
Molecular Formula: C20H34AuO9PS
Supplemental Information: This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Auranofin is a gold(I)-phosphine thiolate small molecule described to produce antiinflammatory and antiarthritic effects. Auranofin is described to block IgE (anti-IgE) and non-IgE histamine release from basophils and to inhibit the de novo synthesis of sulfidopeptide leukotriene C4 (LTC4) induced by anti-IgE from basophils and mast cells. At low concentrations, auranofin is described to stimulate leukotriene B4 (LTB4) synthesis through induction of LTA hydrolase activity, and at high concentrations is described to completely block all lipoxygenase products through inhibition of 5-LO (5-lipoxygenase)/LTA synthase. Auranofin also inhibits IκB kinase (IKK) by modifying Cys179 of the IKKβ subunit. Mitochondrial membrane permeability transition was induced by auranofin in the presence of Ca2+ ions, and demonstrated potent inhibition of mitochondrial thioredoxin reductase through interaction with the active site selenol group. Auranofin and other Au(I) compounds are described to quench reactive singlet oxygen species. Auranofin is an inhibitor of GSTP1, Stat3 and TrxR2.


1. Corey, E.J., et al. 1987. Science. 236: 68-69. PMID: 3563489
2. Columbo, M., et al. 1990. Biochem. Pharmacol. 39: 285-291. PMID: 2105731
3. Betts, W.H., et al. 1990. Biochem. Pharmacol. 39: 1233-1237. PMID: 2157444
4. Rudkowski, R., et al. 1991. Biochem. Pharmacol. 41: 1921-1929. PMID: 1645553
5. Rigobello, M.P., et al. 2002. Br. J. Pharmacol. 136: 1162-1168. PMID: 12163349

Physical State :
Solubility :
Soluble in DMSO (≥5 mg/ml), 100% ethanol (4 mg/ml), chloroform, and methanol.
Storage :
Store at room temperature
Melting Point :
112-155° C
Optical Activity :
α20/D -58.6°, c = 1 in chloroform
IC50 :
TrxR: IC50 = 20 nM (human)
Ki Data :
The NADPH-reduced form of human cytosolic TrxR: Ki= 4 nM (human)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
PubChem CID :
Merck Index :
14: 878
MDL Number :
EC Number :
Beilstein Registry :

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Auranofin  Product Citations

See how others have used Auranofin. Click on the entry to view the PubMed entry .

Citations 1 to 10 of 19 total

PMID: # 30873389  Liu, H. et al. 2019. Front Cell Infect Microbiol. 9: 37.

PMID: # 31378680  Yin, N.|Liu, Y.|Khoor, A.|Wang, X.|Thompson, EA.|Leitges, M.|Justilien, V.|Weems, C.|Murray, NR.|Fields, AP.| et al. 2019. Cancer Cell. 36: 156-167.e7.

PMID: # 30861284  Fidyt, K.|Pastorczak, A.|Goral, A.|Szczygiel, K.|Fendler, W.|Muchowicz, A.|Bartlomiejczyk, MA.|Madzio, J.|Cyran, J.|Graczyk-Jarzynka, A.|Jansen, E.|Patkowska, E.|Lech-Maranda, E.|Pal, D.|Blair, H.|Burdzinska, A.|Pedzisz, P.|Glodkowska-Mrowka, E.|Demkow, U.|Gawle-Krawczyk, K.|Matysiak, M.|Winiarska, M.|Juszczynski, P.|Mlynarski, W.|Heidenreich, O.|Golab, J.|Firczuk, M.| et al. 2019. Mol Oncol. 13: 1180-1195.

PMID: # 31028540  Skaga, E.|Skaga, IØ.|Grieg, Z.|Sandberg, CJ.|Langmoen, IA.|Vik-Mo, EO.| et al. 2019. J. Cancer Res. Clin. Oncol. 145: 1495-1507.

PMID: # 31298580  Tharmalingam, N.|Ribeiro, NQ.|da Silva, DL.|Naik, MT.|Cruz, LI.|Kim, W.|Shen, S.|Dos Santos, JD.|Ezikovich, K.|D'Agata, EM.|Mylonakis, E.|Fuchs, BB.| et al. 2019. Future Med Chem. 11: 1417-1425.

PMID: # 31231607  Dabiri, Y.|Abu El Maaty, MA.|Chan, HY.|Wölker, J.|Ott, I.|Wölfl, S.|Cheng, X.| et al. 2019. Front Oncol. 9: 438.

PMID: # 26530353  You, BR. et al. 2016. Oncology reports. 35: 546-51.

PMID: # 27581528  Zhang, L. et al. 2016. Free Radic. Biol. Med. 99: 426-435.

PMID: # 26157704  Schott, C. et al. 2015. Front Oncol. 5: 131.

PMID: # 25729577  Hall, SR. et al. 2015. Pharmacol Res Perspect. 3: e00110.

Citations 1 to 10 of 19 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 125ms
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Angelucci et al Angelucci et al. (PubMed ID 19710012) used Auranofin to prevent parasite detoxification mechanisms by inhibiting thioredoxin-gluthione reductase (TGR), a possible target for the treatment of Schistosomiasis. -SCBT Publication Review
Date published: 2015-07-13
  • y_2020, m_1, d_24, h_12
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.4
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202476, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 28ms

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.